

Appendix 2 and 5 U.S.C., 552b(c)(6), it has been determined that this latter session will be closed because the discussions are likely to reveal personal information concerning individuals associated with the grant applications. This information is exempt from mandatory disclosure.

Anyone wishing to obtain a roster of members or other relevant information should contact Gerald E. Calderone, Ph.D., Agency for Health Care Policy and Research, Suite 400, 2101 East Jefferson Street, Rockville, Maryland 20852, Telephone (301) 594-2462.

Agenda items for this meeting are subject to change as priorities dictate.

Dated: September 14, 1995.

Clifton R. Gaus,

Administrator.

[FR Doc. 95-23604 Filed 9-22-95; 8:45 am]

BILLING CODE 4160-90-M

Food and Drug Administration

[Docket No. 95N-0297]

Animal Drug Export; Syntex® Plus™ Implant

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that Syntex Animal Health has filed an application requesting approval for export of the animal drug Syntex® Plus™ (trenbolone acetate and estradiol benzoate) Implant to Canada.

ADDRESSES: Relevant information on this application may be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact person identified below. Any future inquiries concerning the export of food animal drugs under the Drug Export Amendments Act of 1986 should also be directed to the contact person.

FOR FURTHER INFORMATION CONTACT: Benjamin A. Puyot, Center for Veterinary Medicine (HFV-130), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-1646.

SUPPLEMENTARY INFORMATION: The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide that FDA may approve applications for the export of drugs that are not currently approved in the United States. Section 802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C) of the act requires that the agency review the application within 30

days of its filing to determine whether the requirements of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice in the Federal Register within 10 days of the filing of an application for export to facilitate public participation in its review of the application. To meet this requirement, the agency is providing notice that Syntex Animal Health, Division of Syntex Agribusiness, Inc., 3401 Hillview Ave., Palo Alto, CA 94304, has filed application number 6242 requesting approval for export of the animal drug Syntex® Plus™ (trenbolone acetate and estradiol benzoate) Implant to Canada. The drug is an implant consisting of 8 pellets and it contains 200 milligrams (mg) of trenbolone acetate plus 28 mg of estradiol benzoate. The implant is to be used to increase weight gain and improve feed efficiency in feedlot steers and heifers. The application was received and filed in the Center for Veterinary Medicine on August 30, 1995, which shall be considered the filing date for purposes of the act.

Interested persons may submit relevant information on the application to the Dockets Management Branch (address above) in two copies (except that individuals may submit single copies) and identified with the docket number found in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between 9 a.m. and 4 p.m., Monday through Friday.

The agency encourages any person who submits relevant information on the application to do so by October 5, 1995, and to provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration of the information during the 30-day review period.

This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802 (21 U.S.C. 382)) and under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Veterinary Medicine (21 CFR 5.44).

Dated: September 8, 1995.

Robert C. Livingston,

Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

[FR Doc. 95-23685 Filed 9-22-95; 8:45 am]

BILLING CODE 4160-01-F

[Docket No. 95F-0255]

GE Silicones; Filing of Food Additive Petition

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that GE Silicones has filed a petition proposing that the food additive regulations be amended to provide for the safe use of vinyl-containing siloxanes as a coating on paper and paperboard in contact with food and to provide for the safe use of 1-ethynyl-1-cyclohexanol as an optional inhibitor for the additive. It is also proposed that the regulations be amended to increase the level of platinum catalyst used in the manufacture of vinyl-containing siloxanes to 200 parts per million (ppm).

DATES: Written comments on the petitioner's environmental assessment by October 25, 1995

ADDRESSES: Submit written comments to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 12420 Parklawn Dr., Rockville, MD 20857.

FURTHER INFORMATION CONTACT: Hortense S. Macon, Center for Food Safety and Applied Nutrition (HFS-216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202-418-3086.

SUPPLEMENTARY INFORMATION: Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a petition (FAP 5B4475) has been filed by GE Silicones, c/o 700 13th St., NW., Washington, DC 20005. The petition proposes to amend the food additive regulations in § 176.170 *Components of paper and paperboard in contact with aqueous and fatty foods* (21 CFR 176.170) to provide for the safe use of vinyl-containing siloxanes as a component of coatings for paper and paperboard in contact with food and to provide for the safe use of 1-ethynyl-1-cyclohexanol as an optional inhibitor for the additive. It is also proposed that the regulations be amended to increase the level of platinum catalyst used in the manufacture of vinyl-containing siloxane to 200 ppm.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4 (b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on